Nexstim Plc, a neuromodulation company, engages in the development and marketing of non-invasive brain stimulation technologies in Finland, rest of Europe, North America, and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||€4.71|
|52 Week High||€3.10|
|52 Week Low||€12.30|
|1 Month Change||-13.10%|
|3 Month Change||9.94%|
|1 Year Change||21.39%|
|3 Year Change||-96.76%|
|5 Year Change||-99.63%|
|Change since IPO||-99.98%|
Recent News & Updates
Is Nexstim (HEL:NXTMH) Using Debt In A Risky Way?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
|NXTMH||FI Medical Equipment||FI Market|
Return vs Industry: NXTMH underperformed the Finnish Medical Equipment industry which returned 39.4% over the past year.
Return vs Market: NXTMH exceeded the Finnish Market which returned 19.8% over the past year.
Stable Share Price: NXTMH is more volatile than 90% of Finnish stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: NXTMH's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Finnish stocks.
About the Company
Nexstim Plc, a neuromodulation company, engages in the development and marketing of non-invasive brain stimulation technologies in Finland, rest of Europe, North America, and internationally. The company’s proprietary SmartFocus technology with 3D navigation is the navigated transcranial magnetic stimulation (TMS) approach that is used for therapeutic and diagnostic applications. It offers NBT system, a navigated brain therapy system for the treatment of major depression order or chronic neuropathic pain; and NBS system, a navigated brain stimulation system for pre-surgical mapping of the speech and motor cortices of the brain.
Is Nexstim undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate NXTMH's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate NXTMH's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: NXTMH is unprofitable, so we can't compare its PE Ratio to the European Medical Equipment industry average.
PE vs Market: NXTMH is unprofitable, so we can't compare its PE Ratio to the Finnish market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate NXTMH's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: NXTMH is overvalued based on its PB Ratio (8.3x) compared to the XE Medical Equipment industry average (5.1x).
How is Nexstim forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NXTMH is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: NXTMH is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: NXTMH is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: NXTMH's revenue (35.6% per year) is forecast to grow faster than the Finnish market (3.7% per year).
High Growth Revenue: NXTMH's revenue (35.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if NXTMH's Return on Equity is forecast to be high in 3 years time
How has Nexstim performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NXTMH is currently unprofitable.
Growing Profit Margin: NXTMH is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: NXTMH is unprofitable, but has reduced losses over the past 5 years at a rate of 12% per year.
Accelerating Growth: Unable to compare NXTMH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NXTMH is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (59.7%).
Return on Equity
High ROE: NXTMH has a negative Return on Equity (-102.69%), as it is currently unprofitable.
How is Nexstim's financial position?
Financial Position Analysis
Short Term Liabilities: NXTMH's short term assets (€9.5M) exceed its short term liabilities (€3.0M).
Long Term Liabilities: NXTMH's short term assets (€9.5M) exceed its long term liabilities (€3.9M).
Debt to Equity History and Analysis
Debt Level: NXTMH's debt to equity ratio (116.1%) is considered high.
Reducing Debt: NXTMH had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NXTMH has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: NXTMH has sufficient cash runway for 1.4 years if free cash flow continues to grow at historical rates of 14.9% each year.
What is Nexstim current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NXTMH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NXTMH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NXTMH's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NXTMH's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of NXTMH's dividend in 3 years as they are not forecast to pay a notable one for the Finnish market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mikko Karvinen (45 yo)
Mr. Mikko Karvinen, M.Sc. (Econ.), serves as Chief Executive Officer at Nexstim Plc since June 16, 2020 and also served as an Interim Chief Executive Officer at Nexstim Plc since February 11, 2020 until Ju...
Experienced Management: NXTMH's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.
Experienced Board: NXTMH's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 52.1%.
Nexstim Plc's employee growth, exchange listings and data sources
- Name: Nexstim Plc
- Ticker: NXTMH
- Exchange: HLSE
- Founded: 2000
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: €31.494m
- Shares outstanding: 6.69m
- Website: https://www.nexstim.com
Number of Employees
- Nexstim Plc
- Elimäenkatu 9 B
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/18 17:38|
|End of Day Share Price||2021/09/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.